Want to see TSE:PSYG full AI Analyst Report?
PSYG Stock Chart & Stats
C$0.12
C$0.01(9.09%)
At close: 4:00 PM EST
C$0.12
C$0.01(9.09%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.17
Previous CloseN/A
Volume10.00K
Average Volume (3M)2.26K
Market Cap
C$1.88M
Enterprise ValueC$1.25
Total Cash (Recent Filing)C$505.42K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.62
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding16,129,404
10 Day Avg. Volume3,028
30 Day Avg. Volume2,257
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Growth InitiativesThe share consolidation aims to provide greater flexibility for business development and growth, potentially improving market positioning and stakeholder interests.
Enhanced Research CapabilitiesAppointing a new chair enhances research capabilities in psilocybin-based treatments, supporting long-term development and innovation in psychedelic therapeutics.
Scientific Advisory Board ExpansionStrengthening the Scientific Advisory Board with a leader in psychopharmacology supports ongoing clinical trials and enhances the company's positioning in the psychedelic therapeutics industry.
Bears Say
Financial InstabilityThe company's financial instability, marked by persistent losses and negative equity, poses significant risks to its ability to sustain operations without external support.
Cash Flow IssuesPoor cash flow management and reliance on external funding indicate liquidity concerns, which could hinder the company's long-term financial health and operational sustainability.
Lack Of Revenue GenerationThe absence of revenue generation and negative profit margins reflect stagnant financial performance, challenging the company's ability to achieve profitability and sustain growth.
Psyence Group News
PSYG FAQ
What was Psyence Group’s price range in the past 12 months?
Psyence Group lowest stock price was C$0.11 and its highest was C$0.17 in the past 12 months.
What is Psyence Group’s market cap?
Psyence Group’s market cap is C$1.88M.
When is Psyence Group’s upcoming earnings report date?
Psyence Group’s upcoming earnings report date is Aug 31, 2026 which is in 25 days.
How were Psyence Group’s earnings last quarter?
Currently, no data Available
Is Psyence Group overvalued?
According to Wall Street analysts Psyence Group’s price is currently Overvalued.
Does Psyence Group pay dividends?
Psyence Group does not currently pay dividends.
What is Psyence Group’s EPS estimate?
Psyence Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Group have?
Psyence Group has 16,129,404 shares outstanding.
What happened to Psyence Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Group?
Currently, no hedge funds are holding shares in TSE:PSYG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Psyence Group
Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.